Program
TQB3201
A development code. Also written as “TQB3201 tablets”.
In Sino Biopharmaceutical's pipeline, AR PROTAC
. Its studies are mostly in Prostatic Neoplasms, led by Sino Biopharmaceutical.
Furthest: phase 2, since Sep 8, 20251 company-led study, 1 open or runningNext primary completion: Apr 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 2since Sep 8, 2025 | Sep 8, 2025 | Apr 2027phase 2 · NCT07172126 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB3201
, phase 1, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2025First study: phase 2 study in Metastatic Castration-resistant Prostate CancerFirst studyNCT07172126 · 291 planned · China
Ahead
- Apr 2027Primary completion: phase 2 study in Metastatic Castration-resistant Prostate CancerNCT07172126
TargetBeta
“AR PROTAC”the company's pipeline, read by Claude · source
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| enzalutamiderule | Astellas Pharma | phase 4 | 69 |
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07172126Metastatic Castration-resistant Prostate Cancer · China | 2 | Not yet recruiting | Apr 2027 | 291 |
How it is read
Names in the registry
- “TQB3201 tablets”, 1 entry
Codes read as this program: TQB3201.
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.